Project Grant R01HL184098
Award Date 9/1/26
Completion Date 5/31/30
Dollars Obligated $854K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
West Hollywood, CA 90048, USA
Similar Awards
- The National Institute on Drug Abuse awarded The Regents of the University of California, San Francisco $246,000 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate the concurrent use of cannabis and stimulant medications on cardiovascular disease risk. The research will evaluate whether cannabis smoking and prescribed stimulant medication used together exert additive or synergistic effects on cardiovascular function and circulating biomarkers of...
- The National Heart, Lung, and Blood Institute awarded Cedars-Sinai Medical Center $717,680 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate immune epithelial niche mechanisms underlying post-viral lung fibrosis. The research examines how anti-viral CD8+ T cell immunity, specifically interferon-gamma signaling and macrophage-derived interleukin-1 beta secretion, impairs alveolar epithelial repair following severe respiratory viral infections. The...
- The National Heart, Lung, and Blood Institute awarded Cedars-Sinai Medical Center $1.379 million on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate cardioprotective mechanisms of Y RNA signaling in macrophages as a potential therapeutic approach to myocardial infarction. The research dissects how a small non-coding RNA called YREX3—secreted by therapeutically-enhanced cardiac stromal cells—signals macrophages to enhance their capacity for...
- The National Heart, Lung, and Blood Institute awarded the University of California, Los Angeles $1.368 million on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanosensitive signaling mechanisms that support endothelial cell resilience in the context of cardiovascular disease treatment. The research elucidates a mechanosensitive signaling domain in endothelial cells and tests how TRPV4-mediated calcium signaling promotes vascular resilience....
- The National Heart, Lung, and Blood Institute awarded Cedars-Sinai Medical Center $1.481 million on July 6, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate single-cell proteome heterogeneity arising from myosin heavy chain 7 (MYH7) mutations associated with hypertrophic cardiomyopathy and the recovery mechanisms induced by the therapeutic agent mavacamten. The research applies high-sensitivity mass spectrometry and single-cell proteomics to quantify over...
- The National Heart, Lung, and Blood Institute of the Department of Health and Human Services awarded the University of California, Los Angeles $3,134,805 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on alternative polyadenylation in cardiovascular disease. The recipient will integrate computational techniques with molecular, cellular, and animal model studies to elucidate how alternative polyadenylation (APA) contributes to cardiovascular...
- The National Heart Lung and Blood Institute awarded the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center $852,991 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a longitudinal study of coronary inflammation detection using computed tomography. The recipient will measure epicardial fat density and peri-coronary fat attenuation in 17,138 non-contrast cardiac CT scans drawn from the Multi-Ethnic Study of Atherosclerosis...
- The National Institute on Drug Abuse awarded Carnegie Mellon University $191,250 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate THC exposure and inhibitory circuit plasticity in the neocortex. The research examines acute and long-term effects of tetrahydrocannabinol (THC), the main psychoactive component of cannabis, on neocortical interneurons expressing the highest levels of cannabinoid receptors in the mammalian brain. The project will...
- The National Heart Lung and Blood Institute awarded Icahn School of Medicine at Mount Sinai $763,862 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the metabolic control of immune cell function in atherogenesis. The research examines the role of methylmalonic acid (MMA)—a byproduct of propionyl-CoA catabolism—in macrophage inflammatory processes that drive atherosclerotic cardiovascular disease. Preliminary data show that genetic deficiency of...
- The National Institute on Drug Abuse awarded the University of California, San Diego $1,233,586 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate epigenetic and neuroimmune mechanisms underlying cannabis-cannabinoid neuroimmunomodulation in people living with HIV. The recipient will conduct integrated clinical, postmortem, and mechanistic research examining how THC and CBD reshape the neuroimmune axis in people living with HIV through...